Key Points Adjusted EPS reached $2.77 in Q2, topping estimates by $0.09, but fell year over year. Revenue rose 5.8% year over year to $23.7 billion, exceeding estimates by $889 million. Full-year 2025 ...

PepsiCo’s beverage segment continues to lose share, and its formerly fast-growing snack business is being hit by weak ...

Early trading on Wall Street was quietly mixed as markets shift their attention toward a deluge of corporate earnings reports ...

Brunswick Corporation faces short-term revenue and profit declines due to weak boat sales, economic headwinds, and tariff ...

J&J (NYSE:JNJ) stock surges rallying peers despite Trump's latest tariff threats on pharma as the company posts a quarterly ...

Trump’s tariffs and the trade war continue to roil global markets. Follow along for live updates on the Dow, S&P 500 and Nasdaq.

Johnson & Johnson is leading the S&P 500 and the Dow Jones Industrial Average after the drugmaker slashed its estimate for the impact of tariffs in 2025 and raised its outlook. The company’s stock is ...

J&J reported second quarter earnings Tuesday. The company is under scrutiny by investors as it faces drug patent cliffs.

Shares of Johnson & Johnson climbed 4.5% in morning trading, enough to pace the S&P 500 index's SPX gainers. They were also headed for the biggest one-day gain since they rallied 4.6% on May 1, 2024.

Moody's (MCO) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good ...

U.S. stocks opened moderately higher on Wednesday, boosted by a tamer-than-expected inflation reading and blowout quarterly ...